Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
7.23
-0.22 (-2.89%)
At close: Sep 12, 2025, 4:00 PM EDT
7.22
0.00 (-0.07%)
After-hours: Sep 12, 2025, 7:54 PM EDT
Terns Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
632.70M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 1.00M | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TERN News
- 3 days ago - Terns Pharmaceuticals, Inc. (TERN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Terns Pharmaceuticals, Inc. - TERN-701 Investor Educational Webinar Transcript - Seeking Alpha
- 23 days ago - Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 - GlobeNewsWire
- 5 weeks ago - Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 weeks ago - Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 2 months ago - Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts - Seeking Alpha
- 2 months ago - Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions - GlobeNewsWire
- 3 months ago - Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences - GlobeNewsWire